GIP and metabolic dysfunction-associated steatotic liver disease: All studies showed the superiority of dual GIP/GLP-1RA, GCGR/GLP-1RA or GLP-1RA in decreasing the intrahepatic lipid content in individuals with MASLD and T2D.